Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 367.40
TGTX's Cash to Debt is ranked higher than
76% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. TGTX: 367.40 )
TGTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 367.4

Equity to Asset 0.87
TGTX's Equity to Asset is ranked higher than
89% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TGTX: 0.87 )
TGTX' s 10-Year Equity to Asset Range
Min: 0.16   Max: 0.97
Current: 0.87

0.16
0.97
F-Score: 2
Z-Score: 36.08
M-Score: -4.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -29588.82
TGTX's Operating margin (%) is ranked lower than
51% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. TGTX: -29588.82 )
TGTX' s 10-Year Operating margin (%) Range
Min: -141552.63   Max: -59
Current: -29588.82

-141552.63
-59
Net-margin (%) -28057.89
TGTX's Net-margin (%) is ranked lower than
51% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. TGTX: -28057.89 )
TGTX' s 10-Year Net-margin (%) Range
Min: -95121.05   Max: -63.97
Current: -28057.89

-95121.05
-63.97
ROE (%) -82.56
TGTX's ROE (%) is ranked higher than
62% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. TGTX: -82.56 )
TGTX' s 10-Year ROE (%) Range
Min: -3919.22   Max: -39.16
Current: -82.56

-3919.22
-39.16
ROA (%) -72.42
TGTX's ROA (%) is ranked higher than
58% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. TGTX: -72.42 )
TGTX' s 10-Year ROA (%) Range
Min: -543.33   Max: 6.57
Current: -72.42

-543.33
6.57
ROC (Joel Greenblatt) (%) -6716.70
TGTX's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. TGTX: -6716.70 )
TGTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -118950   Max: -1066.67
Current: -6716.7

-118950
-1066.67
EBITDA Growth (3Y)(%) -75.20
TGTX's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. TGTX: -75.20 )
TGTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 9
Current: -75.2

0
9
» TGTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TGTX Guru Trades in

TGTX Guru Trades in

TGTX Guru Trades in

Q3 2014

TGTX Guru Trades in Q3 2014

Jim Simons 11,199 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.20
TGTX's P/B is ranked higher than
68% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. TGTX: 9.20 )
TGTX' s 10-Year P/B Range
Min: 0   Max: 15.4
Current: 9.2

0
15.4
P/S 3078.70
TGTX's P/S is ranked higher than
55% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. TGTX: 3078.70 )
TGTX' s 10-Year P/S Range
Min: 0   Max: 3657.1
Current: 3078.7

0
3657.1
EV-to-EBIT -13.32
TGTX's EV-to-EBIT is ranked lower than
55% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TGTX: -13.32 )
TGTX' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 5.3
Current: -13.32

0.1
5.3
Current Ratio 8.61
TGTX's Current Ratio is ranked higher than
84% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. TGTX: 8.61 )
TGTX' s 10-Year Current Ratio Range
Min: 0.06   Max: 35.5
Current: 8.61

0.06
35.5
Quick Ratio 8.61
TGTX's Quick Ratio is ranked higher than
85% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. TGTX: 8.61 )
TGTX' s 10-Year Quick Ratio Range
Min: 0.06   Max: 35.5
Current: 8.61

0.06
35.5
Days Sales Outstanding 129.67
TGTX's Days Sales Outstanding is ranked higher than
72% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. TGTX: 129.67 )
TGTX' s 10-Year Days Sales Outstanding Range
Min: 13.15   Max: 91.25
Current: 129.67

13.15
91.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.06
TGTX's Price/Net Cash is ranked higher than
83% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 55.00 vs. TGTX: 11.06 )
TGTX' s 10-Year Price/Net Cash Range
Min: 0.01   Max: 28.45
Current: 11.06

0.01
28.45
Price/Net Current Asset Value 11.06
TGTX's Price/Net Current Asset Value is ranked higher than
82% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 31.07 vs. TGTX: 11.06 )
TGTX' s 10-Year Price/Net Current Asset Value Range
Min: 0.01   Max: 28.45
Current: 11.06

0.01
28.45
Price/Tangible Book 9.47
TGTX's Price/Tangible Book is ranked higher than
74% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. TGTX: 9.47 )
TGTX' s 10-Year Price/Tangible Book Range
Min: 0.01   Max: 25.04
Current: 9.47

0.01
25.04
Price/DCF (Projected) 40.95
TGTX's Price/DCF (Projected) is ranked higher than
91% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TGTX: 40.95 )
TGTX' s 10-Year Price/DCF (Projected) Range
Min: 5.36   Max: 313
Current: 40.95

5.36
313
Earnings Yield (Greenblatt) -7.70
TGTX's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. TGTX: -7.70 )
TGTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.6   Max: 1470.1
Current: -7.7

-11.6
1470.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:NKB2.Germany,
TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.
» More Articles for TGTX

Headlines

Articles On GuruFocus.com
comment on TGTX Mar 09 2013 
comment on TGTX Mar 09 2013 

More From Other Websites
TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events Jan 21 2015
TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jan 20 2015
TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at... Jan 15 2015
TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at... Jan 15 2015
TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
TG THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 07 2015
TG THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 17 2014
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors Dec 17 2014
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors Dec 17 2014
TG Therapeutics, Inc. (TGTX) in Focus: Stock Soars 21.2% Dec 12 2014
TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 09 2014
Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in... Dec 09 2014
Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical... Dec 08 2014
Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta... Dec 06 2014
TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With... Dec 01 2014
TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With... Dec 01 2014
TG Therapeutics, Inc. to Present at the 2014 Deutsche Bank BioFEST Conference Nov 25 2014
Will TG Therapeutics (TGTX) Continue to Surge Higher? Nov 25 2014
TG THERAPEUTICS, INC. Financials Nov 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK